Prioritizing Commercialization Decisions in Early Stages of Advanced Therapy Development: An Overview from Gwen Erskine, Senior Director of Consulting Services
Successful biopharmaceutical organizations begin developing a commercialization strategy in early stages. Instead of waiting until their advanced therapy or biologics product is closer to pivotal trial stages, developers should confront these decisions as soon as possible.
In a recent interview with Pharmaceutical Commerce, Gwen Erskine, Senior Director of Consulting Services at Cryoport Systems, illustrates why prioritizing commercialization readiness during early phases of development optimizes profitability, flexibility, and risk management.
Delayed Commercialization Strategy May Lead to Increased Operational Risk
When teams think proactively about their commercial strategy, they can better avoid costly delays, process redesigns, or repeated studies in the development process. Waiting until later stages creates room for greater risk, and the realization that your commercial strategy is not viable at scale, Erskine explains.
For leadership teams, this doesn’t mean establishing a full-scale commercial structure immediately. But it does require early evaluation of packaging configurations, logistics strategies, manufacturing approaches, and distribution networks with long-term implications in mind.
Otherwise, Erskine emphasizes that delays to key milestones can erode investor confidence, extend launch timelines, and diminish competitive advantage in increasingly complex biopharma markets.
Key Considerations to Prioritize in Early Stages of Development
It’s important that developers expand their priorities beyond just clinical results and consider the full product journey when developing a vision for commercialization of biologics or advanced therapy products. A successful strategy involves understanding what a reliable supply chain consists of, regulatory and operational risks, and the structure of their clinical and commercial teams.
Developers face increasing complexity in terms of launch readiness. They cannot solely consider regulatory approval of their products. Understanding how to meet commercial demand across providers, patients, and geographical locations is key. Organizations should address operational details early on, such as practical product handling requirements, product configuration, transportation plans, temperature management needs, and their full supply chain design.
According to Erskine, internal team alignment must also be top of mind to create the operational foundation needed for therapies to scale efficiently. Development, regulatory, quality, operations, and commercial teams need to remain regularly connected and communicate openly to avoid mishaps and conflicts later down the line in the therapy journey. When cross-functional teams are aligned on priorities and time constraints, they create operational flexibility and reliability, which are essential for commercial success.
The Right Partner Has a Strategic Approach Toward the Product Journey
Successful organizations keep a long-term strategy top of mind during every phase of development. They understand that every step of the process has implications toward the end goal, requiring not only disciplined execution but documentation, communication, and a forward-thinking commercialization strategy. That way, they’re able to back up their decisions with data, remain aware of potential risks, and address challenges proactively instead of waiting until a later stage when changes are harder to implement.
Erskine also emphasizes the importance of selecting a proactive partner who understands your program from start to finish and anticipates future needs. Cryoport Systems supports biopharma developers across the full development and commercialization journey with temperature-controlled supply chain solutions. Navigating the complex biologics and advanced therapy environment with a forward-thinking approach is crucial to successful commercialization.
Read the full article for more insights.
